The value of serum Sema4D level in predicting the prognosis of patients with acute ST-segment elevation myocardial infarction and with high thrombus burden

Jie Bai; Liang Chen; Louyuan Xu; Qingquan Zhang; Jun Liu; Koulong Zheng

doi:10.1186/s12872-023-03244-5

The value of serum Sema4D level in predicting the prognosis of patients with acute ST-segment elevation myocardial infarction and with high thrombus burden

BMC Cardiovasc Disord. 2023 May 3;23(1):230. doi: 10.1186/s12872-023-03244-5.

Authors

Jie Bai^#¹, Liang Chen^#¹, Louyuan Xu¹, Qingquan Zhang¹, Jun Liu¹, Koulong Zheng²

Affiliations

¹ Department of Cardiology, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital , Nantong, 226001, Jiangsu, China.
² Department of Cardiology, Affiliated Hospital 2 of Nantong University, Nantong First People's Hospital , Nantong, 226001, Jiangsu, China. zklsir@126.com.

^# Contributed equally.

Abstract

Background: Acute ST-segment elevation myocardial infarction (STEMI) is a serious cardiovascular disease. High thrombus burden is an independent risk factor for poor prognosis of acute myocardial infarction. However, there is no study on the correlation between soluble semaphorin 4D (sSema4D) level and high thrombus burden in patients with STEMI.

Purpose: This study aimed to investigate the relationship between sSema4D level and the thrombus burden of STEMI and further explore its effect on the main predictive value of the occurrence of major adverse cardiovascular events (MACE).

Methods: From October 2020 to June 2021, 100 patients with STEMI diagnosed in our hospital's cardiology department were selected. According to the thrombolysis in myocardial infarction(TIMI)score, STEMI patients were divided into high thrombus burden groups (55 cases) and non-high thrombus burden groups (45 cases) 0.74 patients with stable coronary heart disease (CHD) were selected as stable CHD group, and 75 patients with negative coronary angiography (CAG) were selected as control group. Serum sSema4D levels were measured in 4 groups. The correlation between serum sSema4D and high-sensitivity C-reactive protein (hs-CRP) in patients with STEMI was analyzed. The relationship of serum sSema4D levels between the high and non-high thrombus burden group was evaluated. The effect of sSema4D levels on the occurrence of MACE was explored in one year after percutaneous coronary intervention.

Results: Serum sSema4D level was positively correlated with hs-CRP level in STEMI patients (P < 0.05) with a correlation coefficient of 0.493. The sSema4D level was significantly higher in the high versus non-high thrombus burden group (22.54(20.82,24.17), P < 0.05). Moreover, MACE occurred in 19 cases in high thrombus burden group and 3 cases in non-high thrombus burden group. The results of Cox regression analysis showed that sSema4D was an independent predictor of MACE (OR = 1.497,95% CI: 1.213-1.847, P < 0.001).

Conclusion: The sSema4D level is associated with coronary thrombus burden and is an independent risk factor for MACE.

Keywords: Acute myocardial infarction; High thrombus burden; MACE; hs-CRP; sSema4D.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anterior Wall Myocardial Infarction* / etiology
C-Reactive Protein
Humans
Myocardial Infarction* / diagnosis
Myocardial Infarction* / etiology
Myocardial Infarction* / therapy
Percutaneous Coronary Intervention* / adverse effects
Prognosis
ST Elevation Myocardial Infarction* / diagnostic imaging
ST Elevation Myocardial Infarction* / therapy
Thrombosis* / etiology
Treatment Outcome

Substances

CD100 antigen
C-Reactive Protein